Complete financial analysis of Medexus Pharmaceuticals Inc. (MEDXF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medexus Pharmaceuticals Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Cia. Hering (HGTX3.SA) Income Statement Analysis – Financial Results
- TGC Ventures International, Inc. (TGVN) Income Statement Analysis – Financial Results
- TAT Technologies Ltd. (TATT.TA) Income Statement Analysis – Financial Results
- Infratil Limited (IFUUF) Income Statement Analysis – Financial Results
- Information Services Corporation (IRMTF) Income Statement Analysis – Financial Results
Medexus Pharmaceuticals Inc. (MEDXF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.medexus.com
About Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 113.05M | 108.10M | 76.70M | 79.66M | 52.43M | 25.36M | 7.75M | 4.65M | 2.89M | 3.69M | 3.07M | 0.00 | 0.00 |
| Cost of Revenue | 53.54M | 48.06M | 38.77M | 37.66M | 22.99M | 10.38M | 3.85M | 2.08M | 998.43K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 59.51M | 60.04M | 37.93M | 42.01M | 29.44M | 14.98M | 3.90M | 2.57M | 1.89M | 3.69M | 3.07M | 0.00 | 0.00 |
| Gross Profit Ratio | 52.64% | 55.54% | 49.45% | 52.73% | 56.15% | 59.08% | 50.37% | 55.24% | 65.44% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 8.04M | 2.94M | 5.87M | 4.60M | 1.10M | 0.00 | 0.00 | 0.00 | 0.00 | 542.62K | 1.38M | 0.00 | 0.00 |
| General & Administrative | 27.86M | 36.86M | 34.52M | 19.28M | 11.77M | 5.64M | 1.58M | 2.15M | 2.72M | 1.21M | 2.02M | 149.56K | 136.14 |
| Selling & Marketing | 10.58M | 11.39M | 9.51M | 16.89M | 17.16M | 9.97M | 4.51M | 2.95M | 2.48M | 3.15M | 4.70M | 0.00 | 0.00 |
| SG&A | 38.44M | 48.25M | 44.03M | 36.17M | 28.93M | 15.62M | 6.09M | 5.10M | 5.20M | 4.36M | 6.72M | 149.56K | 136.14 |
| Other Expenses | 2.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.72M | 51.55M | 50.30M | 41.27M | 30.48M | 15.66M | 6.10M | 5.12M | 5.28M | 4.90M | 8.10M | 149.56K | 136.14 |
| Cost & Expenses | 102.26M | 99.61M | 89.08M | 78.93M | 53.47M | 26.04M | 9.95M | 7.20M | 6.28M | 4.90M | 8.10M | 149.56K | 136.14 |
| Interest Income | 0.00 | 0.00 | 0.00 | 3.00K | 205.89K | 161.72K | 30.82K | 29.96K | 31.95K | 23.21K | 49.23K | 0.00 | 0.00 |
| Interest Expense | 13.36M | 13.61M | 12.22M | 9.82M | 6.44M | 2.90M | 918.90K | 501.78K | 732.52K | 269.44K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.81M | 8.05M | 7.71M | 7.90M | 5.26M | 2.38M | 231.16K | 51.87K | 113.48K | 88.12K | 0.00 | 0.00 | 0.00 |
| EBITDA | 19.28M | 14.65M | 15.16M | -23.61M | 7.04M | 159.00K | -2.06M | -697.72K | -1.15M | -3.85M | -4.88M | -2.02M | -136.14 |
| EBITDA Ratio | 17.05% | 13.48% | -8.12% | 8.43% | 3.25% | 5.58% | -25.62% | -59.93% | -113.69% | -31.76% | -159.09% | 0.00% | 0.00% |
| Operating Income | 10.79M | 7.61M | -15.00M | -1.38M | -5.41M | -4.39M | -2.18M | -592.05K | -1.03M | -1.21M | -4.88M | -149.56K | -136.14 |
| Operating Income Ratio | 9.55% | 7.04% | -19.55% | -1.73% | -10.32% | -17.32% | -28.09% | -12.72% | -35.72% | -32.78% | -159.09% | 0.00% | 0.00% |
| Total Other Income/Expenses | -10.69M | -12.66M | 11.18M | -30.13M | 244.00K | -477.99K | -501.00K | -584.12K | -431.64K | 38.83K | -117.08K | 0.00 | 0.00 |
| Income Before Tax | 106.00K | -5.04M | -3.82M | -31.50M | -5.19M | -4.72M | -2.70M | -1.37M | -1.77M | -3.22M | -5.00M | -149.56K | -136.14 |
| Income Before Tax Ratio | 0.09% | -4.66% | -4.98% | -39.54% | -9.89% | -18.60% | -34.79% | -29.51% | -61.31% | -87.14% | -162.90% | 0.00% | 0.00% |
| Income Tax Expense | 320.00K | -6.26M | -941.00K | -3.24M | -790.44K | 166.29K | 918.90K | 501.78K | 732.52K | 269.44K | 0.00 | 0.00 | 0.00 |
| Net Income | -214.00K | 1.22M | -2.88M | -28.26M | -4.40M | -4.88M | -2.70M | -1.37M | -1.77M | -3.22M | -5.00M | -149.56K | -136.14 |
| Net Income Ratio | -0.19% | 1.13% | -3.75% | -35.48% | -8.39% | -19.26% | -34.79% | -29.51% | -61.31% | -87.14% | -162.90% | 0.00% | 0.00% |
| EPS | -0.01 | 0.06 | -0.15 | -1.86 | -0.31 | -0.49 | -0.47 | -0.28 | -0.37 | -0.67 | -0.07 | -0.27 | 0.00 |
| EPS Diluted | -0.01 | 0.06 | -0.14 | -1.86 | -0.31 | -0.49 | -0.47 | -0.28 | -0.37 | -0.67 | -0.07 | -0.27 | 0.00 |
| Weighted Avg Shares Out | 22.32M | 19.98M | 19.45M | 15.20M | 14.36M | 9.91M | 5.68M | 4.84M | 4.83M | 4.80M | 72.06M | 544.00K | 177.78K |
| Weighted Avg Shares Out (Dil) | 22.32M | 20.52M | 19.86M | 15.20M | 14.36M | 9.91M | 5.68M | 4.84M | 4.83M | 4.80M | 72.06M | 544.00K | 177.78K |
Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 18, 2024) - Earlier in November 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) successfully completed a negotiation process with the pan-Canadian Pharmaceutical Alliance seeking to make Trecondyv® (treosulfan for injection) accessible to...
Medexus Pharmaceuticals Inc. (MEDXF) Q2 2025 Earnings Call Transcript
Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q2 2025 Earnings Conference Call November 8, 2024 8:00 AM ET Company Participants Victoria Rutherford - IR, Adelaide Capital Ken d'Entremont - CEO Brendon Bushman - CFO Conference Call Participants Andre Uddin - Research Capital Michael...
Medexus Announces Strong Fiscal Q2 2025 Results
Fiscal Q2 2025 revenue of $26.3 million, net income of $0.1 million, operating income of $1.6 million, and Adjusted EBITDA* of $6.0 million Management to host conference call at 8:00 AM Eastern time on Friday, November 8, 2024 Toronto, Ontario...
Medexus Schedules Second Fiscal Quarter 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 29, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, November 8, 2024 to discuss Medexus's results for its second...
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 19, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareholders elected all nominees listed in Medexus's management information circular dated August 7, 2024...
Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 16, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the US Food and Drug Administration has extended the review...
Medexus Announces Strong Fiscal Q1 2025 Results
Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA* of $6.1 million Management to host conference call at 8:00 AM Eastern time on Thursday, August 8, 2024 Toronto, Ontario...
Medexus Schedules First Fiscal Quarter 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August 8, 2024 to discuss Medexus's results for its first...
Medexus Pharmaceuticals Inc. (MEDXF) Q4 2024 Earnings Call Transcript
Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q4 2024 Earnings Conference Call June 26, 2024 8:00 AM ET Company Participants Victoria Rutherford - IR, Adelaide Capital Kenneth d'Entremont - CEO Marcel Konrad - CFO Conference Call Participants Andre Uddin - Research Capital Michael...
Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024
FDA has Accepted for Review the Treosulfan NDA Management to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF)...
Source: https://incomestatements.info
Category: Stock Reports